Work

OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx362.065

Authors: A. Tutt, B. Kaufman, J. Garber, R. Gelber, E. McFadden, C. Goessl, G. Viale, C. Geyer, D. Zardavas, A. Arahmani, D. Fumagalli, E. De Azambuja, N. Ponde, P. Herbolsheimer, W. Wu, J. Constantino, P. Rastogi

Institutions: King's College London, Breast Cancer Now, Sheba Medical Center, Dana-Farber Cancer Institute, AstraZeneca (United States), European Institute of Oncology, Virginia Commonwealth University, VCU Massey Comprehensive Cancer Center, Breast International Group, NRG Oncology, University of Pittsburgh

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2763515255

FWCI: 0.819

Cites:

Cited by: 20

Related to: 10